CONTACT
中文
HOME
SCIENCE
PIPELINE
TEAM
NEWS
PRESS RELEASE
PUBLICATION
COLLABORATION
CAREER
PRESS RELEASE
July 18, 2022
ETERN Announces Clinical Trial Collaboration with Merck to Evaluate ET0038 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
October 14, 2021
ETERN Won the "Excellent Enterprise" Award of the 10th China Innovation & Entrepreneurship Competition Biomedical Section
September 1, 2021
ETERN Therapeutics Announces Completion of Series B Financing to Advance the Protein Liquid-Liquid Phase Separation Technology Platform and Accelerate the Development of Novel Drugs to Target “Undruggable” Proteins
July 2, 2021
ET0038, a selective allosteric inhibitor of SHP2, has received the IND approval in Mainland China
May 18, 2021
ET0038, a highly potent and selective allosteric inhibitor of SHP2, received U.S. FDA IND approval
CONTACT
中文